News
FDA Approves New Treatment Option for Ulcerative Colitis
The expanded FDA approval was based on results from two 8-week placebo-controlled induction trials and a 52-week maintenance study.
Your search for tofacitinib returned 4 results
News
FDA Approves New Indication for Xeljanz, Xeljanz XR
The new PsA approval was based on data from the Phase 3 OPAL Broaden, OPAL Beyond, and OPAL Balance studies.
Drugs in the Pipeline
Xeljanz Under FDA Review for Psoriatic Arthritis
An anticipated Prescription Drug User Fee Act (PDUFA) action date of December 2017 has been set by the FDA for both Xeljanz sNDAs.
News
Tofacitinib Goes Head-to-Head with Adalimumab in RA Study
Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.
